Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction

• US 20050267072A1
• Filed: 05/12/2005
• Published: 12/01/2005
• Est. Priority Date: 05/14/2004
• Status: Abandoned Application

• Current Assignee: Solvay Pharmaceuticals GmbH (Abbvie Incorporated)
• Original Assignee: Solvay Pharmaceuticals GmbH (Abbvie Incorporated)
• Inventors: Weske, Michael, Ziegler, Dieter, Witte, Klaus, Straub, Matthias
• Application Number:
  US11/127,162
• Publication Number:
  US 20050267072A1
• Time in Patent Office: Days
• US Class Current: 514/80
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to the novel medicinal use of dually acting compounds capable of inhibiting neutral endopeptidase (=NEP) and human soluble endopeptidase (=hSEP) in the prophylaxis and/or treatment of sexual dysfunction in mammals and humans.

Claims

1. A method of treating or inhibiting sexual dysfunction in a human or other mammal subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a dually acting compound capable of inhibiting neutral endopeptidase and human soluble endopeptidase.

2. A method according to claim 1, wherein said compound is a compound corresponding to Formula I

wherein

R¹ is hydrogen or a group forming a biolabile carbonic acid ester,

A represents a group selected from the subgroups a,

wherein

R² is hydrogen or a a group forming a biolabile carbonic acid ester and

R³ is a phenyl-C_1-4-alkyl group which can optionally be substituted in the phenyl ring by C_1-4-alkyl, C_1-4-alkoxy or halogen;

or a naphthyl-C_1-4-alkyl group, and b,

wherein

R⁴ is hydrogen or a group forming a biolabile phosphonic acid ester, and

R⁵ is hydrogen or a group forming a biolabile phosphonic acid ester,

or a physiologically compatible salt thereof.

3. A method according to claim 1, wherein said compound is a compound corresponding to Formula Ia,

wherein

R¹ is hydrogen or a group forming a biolabile carbonic acid ester,

R² is hydrogen or a group forming a biolabile carbonic acid ester and

R³ is a phenyl-C_1-4-alkyl group which can optionally be substituted in the phenyl ring by C_1-4-alkyl, C_1-4-alkoxy or halogen;

or a naphthyl-C_1-4-alkyl group,

or a physiologically compatible salt thereof.

4. A method according to claim 1, wherein said compound is selected from the group consisting of:

2-[1-(1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-cyclopentylmethyl]-4-phenyl-butyric acid ethyl ester;

2-[1-(1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-cyclopentylmethyl]-4-naphthalen-1-yl-butyric acid ethyl ester;

2-[1-(1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-cyclopentylmethyl]-4-phenyl-butyric acid;

2-[1-(1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-cyclopentylmethyl]-4-naphthalen-1-yl-butyric acid;

and physiologically compatible salts thereof.

5. A method according to claim 1, wherein the sexual dysfunction is female sexual dysfunction.

6. A method according to claim 1, wherein the sexual dysfunction is male sexual dysfunction.

7. A method according to claim 6, wherein the male sexual dysfunction is selected from the group consisting of erectile dysfunction, ejaculatory disorders and desire disorders.

8. A method according to claim 7, wherein the male sexual dysfunction is erectile dysfunction.

9. A pharmaceutical combination composition comprising pharmacologically effective quantities of:

a) at least one neutral endopeptidase inhibitor,

b) at least one inhibitor of human soluble endopeptidase, and

c) at least one compound selected from the group consisting of PDE5 inhibitors, NPY receptor antagonists, PDE2 inhibitors, nitric oxide donors, dopamine receptor agonists, melanocortin receptor agonists, potassium channel openers, calcium activated potassium channel openers, α

1-adrenoceptor antagonists, VIP receptor agonists, VIP analogues, α

2-adrenoceptor antagonists, estrogens, medroxyprogesterone, medroxyprogesterone acetate, methyl testosterone hormone replacement therapy agents, testosterone, testostrone replacement agents, testosterone/oestradiol agents, estrogen agonists, serotonin receptor agonists, serotonin receptor antagonists, prostanoid receptor agonists, purinergic receptor agonists, ECE inhibitors, endothelin receptor antagonists, NEP inhibitors and antidepressant agents.

10. A pharmaceutical composition according to claim 9, further comprising at least one pharmaceutically acceptable auxiliary or carrier.

11. A pharmaceutical composition according to claim 9, wherein said at least one neutral endopeptidase inhibitor (a) and said at least one inhibitor of human soluble endopeptidase (b) are present together in the form of a dually acting compound capable of inhibiting both neutral endopeptidase and human soluble endopeptidase.

12. A pharmaceutical composition according to claim 11, wherein said dually acting compound is a compound corresponding to Formula I

wherein

R¹ is hydrogen or a group forming a biolabile carbonic acid ester,

A represents a group selected from the subgroups a,

wherein

R² is hydrogen or a a group forming a biolabile carbonic acid ester and

R³ is a phenyl-C_1-4-alkyl group which can optionally be substituted in the phenyl ring by C_1-4-alkyl, C_1-4-alkoxy or halogen;

or a naphthyl-C_1-4-alkyl group, and b,

wherein

R⁴ is hydrogen or a group forming a biolabile phosphonic acid ester, and

R⁵ is hydrogen or a group forming a biolabile phosphonic acid ester,

or a physiologically compatible salt thereof.

13. A pharmaceutical composition according to claim 9, wherein component c) comprises at least one dopamine receptor agonist.

14. A pharmaceutical composition according to claim 13, wherein said at least one dopamine receptor agonist is selected from the group consisting of apomorphine, Uprima and Ixsene.

15. A kit comprising a plurality of separate containers in a single package, said containers containing pharmaceutical compositions for use in combination and comprising:

a1) in one separate container a pharmaceutical composition comprising at least one neutral endopeptidase inhibitor and in a second separate container a pharmaceutical composition comprising at least one inhibitor of human soluble endopeptidase, or

a2) in one separate container a pharmaceutical composition comprising a dually acting compound capable of inhibiting neutral endopeptidase and human soluble endopeptidase, and

b) in another separate container a pharmaceutical composition comprising at least one compound supportive to the inventive use which is selected from the group consiting of PDE5 inhibitors, NPY receptor antagonists, PDE2 inhibitors, nitric oxide donors, dopamine receptor agonists, melanocortin receptor agonists, potassium channel openers, calcium activated potassium channel openers, α

1-adrenoceptor antagonists, VIP receptor agonists or VIP analogues, α

2-adrenoceptor antagonists, estrogens, medroxyprogesterone, medroxyprogesterone acetate, methyl testosterone hormone replacement therapy agents, testosterone, testostrone replacement agents, testosterone/estradiol agents, estrogen agonists, serotonin receptor agonists, serotonin receptor antagonists, prostanoid receptor agonists, purinergic receptor agonists, ECE inhibitors, endothelin receptor antagonists, NEP inhibitors and antidepressant agents.

16. A method of treating or inhibiting sexual dysfunction in mammals and humans comprising administering to a subject in need thereof therapeutically effective amounts of

a) at least one neutral endopeptidase inhibitor,

b) at least one inhibitor of human soluble endopeptidase, and

c) at least one compound supportive to the inventive use which is selected from the group consisting of PDE5 inhibitors, NPY receptor antagonists, PDE2 inhibitors, nitric oxide donors, dopamine receptor agonists, melanocortin receptor agonists, potassium channel openers, calcium activated potassium channel openers, α

1-adrenoceptor antagonists, VIP receptor agonists or VIP analogues, α

2-adrenoceptor antagonists, estrogens, medroxyprogesterone, medroxyprogesterone acetate, methyl testosterone hormone replacement therapy agents, testosterone, testostrone replacement agents, testosterone/oestradiol agents, estrogen agonists, serotonin receptor agonists, serotonin receptor antagonists, prostanoid receptor agonists, purinergic receptor agonists, ECE inhibitors, endothelin receptor antagonists, NEP inhibitors and antidepressant agents.